USPTO ignites CRISPR/Cas9 patent battle
13-01-2016
Zffoto / Shutterstock.com
A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CRISPR, patent, gene editing, Editas, Broad Institute of MIT and Harvard, University of California
